There is a condition that affects approximately 88 million American adults — more than a third of the adult population — that most of them do not know they have. It is not a disease in the traditional sense. It does not produce dramatic symptoms. It does not send people to emergency rooms or generate headlines. It operates silently, progressively, and with extraordinary patience, reshaping metabolic function over years and decades until the consequences become impossible to ignore: Type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, and possibly Alzheimer's disease and certain cancers.
The condition is insulin resistance. And understanding it — mechanistically, historically, and clinically — is essential to understanding why the chronic disease epidemic of the twenty-first century is happening and what, if anything, can be done about it.
What insulin does
Insulin is a peptide hormone produced by the beta cells of the pancreatic islets of Langerhans. Its primary function is to regulate blood glucose — the concentration of sugar in the bloodstream — by facilitating the uptake and storage of glucose by tissues throughout the body. When blood glucose rises after a meal, beta cells secrete insulin in a biphasic pattern: a rapid first-phase release (within 5-10 minutes) of pre-formed insulin granules, followed by a more sustained second-phase release of newly synthesized insulin over 1-2 hours.
Insulin acts through the insulin receptor — a transmembrane tyrosine kinase receptor expressed on virtually every cell in the body, with particularly high density on hepatocytes (liver cells), adipocytes (fat cells), and skeletal myocytes (muscle cells). Binding of insulin to its receptor activates a signaling cascade involving insulin receptor substrate (IRS) proteins, phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt/PKB), which collectively produce the metabolic effects associated with the "fed state" (Saltiel & Kahn, 2001):
In the liver: Insulin suppresses hepatic glucose production (gluconeogenesis and glycogenolysis), promotes glycogen synthesis for glucose storage, stimulates de novo lipogenesis (synthesis of fatty acids from excess glucose), and promotes VLDL production for triglyceride export.
In skeletal muscle: Insulin stimulates glucose uptake through translocation of GLUT4 glucose transporters to the cell membrane, promotes glycogen synthesis, and stimulates protein synthesis. Skeletal muscle is responsible for approximately 70-80% of insulin-stimulated glucose disposal under normal conditions.
In adipose tissue: Insulin stimulates glucose uptake (for lipogenesis substrate), promotes triglyceride synthesis and storage, and suppresses lipolysis (the breakdown of stored fat into free fatty acids). This anti-lipolytic effect is one of insulin's most potent metabolic actions — it requires only very low insulin concentrations to suppress fat mobilization, which is why even mild hyperinsulinemia can impair fat oxidation.
In the brain: Insulin crosses the blood-brain barrier (through saturable transport) and acts on insulin receptors in the hypothalamus, hippocampus, and cortex, modulating appetite, energy expenditure, and cognitive function. Cerebral insulin signaling is increasingly recognized as important for memory consolidation and neurodegenerative disease risk.
What insulin resistance is
Insulin resistance is a condition in which cells respond less effectively to insulin signaling — requiring progressively higher insulin concentrations to produce the same metabolic effects. In simplified terms: the locks (insulin receptors) are becoming harder to turn, so the body produces more keys (insulin) to compensate.
In the early stages of insulin resistance, the pancreas compensates by increasing insulin production, maintaining normal blood glucose levels through compensatory hyperinsulinemia. This stage — which can persist for years or decades — is metabolically abnormal but does not meet the diagnostic criteria for diabetes because blood glucose remains within the normal range. Standard glucose tests (fasting glucose, hemoglobin A1c) may appear completely normal even when insulin levels are 3-5 times higher than in insulin-sensitive individuals.
This is why insulin resistance is called a "silent" condition: the compensation works — until it does not. When beta cell function eventually declines and can no longer produce sufficient insulin to overcome the resistance, blood glucose rises and the diagnosis shifts to prediabetes, then Type 2 diabetes. The metabolic dysfunction may have been present for 10-15 years before the glucose threshold for diabetes diagnosis is crossed (DeFronzo, 2004).
How insulin resistance develops
The molecular mechanisms of insulin resistance are complex, multifactorial, and incompletely understood. Several interdependent mechanisms contribute:
Lipid overload and lipotoxicity
The most well-established mechanism of insulin resistance involves ectopic lipid accumulation — the deposition of fat in tissues not designed for fat storage. When caloric intake chronically exceeds expenditure, adipose tissue eventually reaches its storage capacity (which varies genetically between individuals). Excess fatty acids then accumulate in liver (producing non-alcoholic fatty liver disease), skeletal muscle (intramyocellular lipid), and pancreas (impairing beta cell function).
In these ectopic sites, fatty acid metabolites — diacylglycerol (DAG) and ceramides — activate inflammatory kinases (protein kinase C isoforms, JNK) that phosphorylate the insulin receptor substrate at serine/threonine residues rather than the normal tyrosine residues, disrupting the insulin signaling cascade. This lipid-induced insulin signaling impairment is the primary molecular mechanism connecting obesity to insulin resistance (Samuel & Shulman, 2016).
Inflammation
As discussed in detail elsewhere, chronic low-grade inflammation — driven by adipose tissue macrophage infiltration and pro-inflammatory cytokine production — independently impairs insulin signaling through activation of JNK and IKKβ inflammatory kinases. The inflammatory and lipotoxic mechanisms of insulin resistance are synergistic: lipid accumulation triggers inflammation, and inflammation exacerbates lipid-induced insulin signaling impairment.
Mitochondrial dysfunction
Mitochondria — the cellular organelles responsible for ATP (energy) production through oxidative phosphorylation — play a central role in insulin resistance. In insulin-resistant individuals, skeletal muscle mitochondria show reduced oxidative capacity, reduced citrate synthase activity, and reduced mitochondrial DNA content — findings consistent with impaired mitochondrial biogenesis and function (Petersen et al., 2004).
Whether mitochondrial dysfunction causes insulin resistance or is a consequence of it remains debated. The evidence suggests bidirectional causality: excess lipid accumulation impairs mitochondrial function through lipid peroxidation and oxidative stress, while impaired mitochondrial fatty acid oxidation capacity contributes to further lipid accumulation — creating a self-reinforcing cycle of metabolic decline.
Endoplasmic reticulum stress
The endoplasmic reticulum (ER) — the cellular organelle responsible for protein folding and lipid synthesis — experiences stress when its folding capacity is overwhelmed by excess nutrient flux. ER stress activates the unfolded protein response (UPR), which, when sustained, triggers inflammatory signaling (JNK, NF-κB activation) and direct inhibition of insulin receptor signaling. Obesity increases ER stress in liver, adipose tissue, and hypothalamus, contributing to both peripheral and central insulin resistance (Ozcan et al., 2004).
The consequences of insulin resistance
Compensatory hyperinsulinemia
The most immediate consequence of insulin resistance is compensatory hyperinsulinemia — elevated circulating insulin levels as the pancreas works harder to overcome the resistance. Hyperinsulinemia itself produces metabolic effects that exacerbate the overall metabolic dysfunction:
- Enhanced lipogenesis. High insulin levels promote hepatic de novo lipogenesis (fat synthesis from carbohydrate), contributing to non-alcoholic fatty liver disease and elevated triglycerides.
- Impaired fat oxidation. Insulin's anti-lipolytic effect, even at relatively low concentrations, suppresses fat mobilization from adipose tissue, making it metabolically difficult for insulin-resistant individuals to access stored body fat for energy.
- Sodium retention. Insulin promotes renal sodium reabsorption, contributing to hypertension.
- Vascular effects. Insulin has both vasodilatory (through nitric oxide) and vasoconstrictive (through endothelin-1) effects. In insulin resistance, the vasodilatory effects are impaired while the vasoconstrictive effects are preserved, contributing to endothelial dysfunction and atherosclerosis.
Non-alcoholic fatty liver disease (NAFLD)
Insulin resistance is the primary driver of NAFLD — now the most common chronic liver disease globally, affecting approximately 25% of the world population. Hepatic insulin resistance promotes unregulated lipogenesis, impaired fatty acid oxidation, and triglyceride accumulation in hepatocytes. NAFLD can progress to non-alcoholic steatohepatitis (NASH — fatty liver with inflammation and fibrosis), cirrhosis, and hepatocellular carcinoma. NAFLD is now the leading indication for liver transplantation in women and the second-leading indication overall (Younossi et al., 2016).
Polycystic ovary syndrome (PCOS)
Insulin resistance is present in approximately 70-80% of women with PCOS and is increasingly recognized as a central driver of the syndrome rather than merely an associated feature. Hyperinsulinemia stimulates ovarian androgen production, suppresses hepatic sex hormone-binding globulin (SHBG) production (increasing free androgen levels), and disrupts the hypothalamic-pituitary-gonadal axis — producing the characteristic features of PCOS: hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology. Metformin and other insulin-sensitizing therapies improve all three domains.
Cardiovascular disease
Insulin resistance drives cardiovascular risk through multiple interconnected mechanisms: dyslipidemia (elevated triglycerides, low HDL, small dense LDL), hypertension, chronic inflammation, endothelial dysfunction, and a prothrombotic state. The metabolic syndrome — a clinical clustering of central obesity, hypertension, dyslipidemia, and glucose intolerance — is essentially a clinical proxy for insulin resistance and identifies individuals at substantially elevated cardiovascular risk.
Measuring insulin resistance
Standard clinical practice does not routinely assess insulin resistance. Fasting glucose and hemoglobin A1c — the standard diabetes screening tests — only become abnormal after insulin resistance has progressed to the point where beta cell compensation fails. Earlier detection requires more sensitive measures:
Fasting insulin. A simple blood test that measures circulating insulin levels. Elevated fasting insulin (typically above 10-12 μU/mL, though cutoffs vary) suggests insulin resistance with compensatory hyperinsulinemia. Inexpensive and widely available, but not routinely ordered.
HOMA-IR. The homeostatic model assessment of insulin resistance — calculated as (fasting glucose × fasting insulin) / 405 — provides a more quantitative estimate than either glucose or insulin alone. Values above 2.0-2.5 suggest insulin resistance.
Oral glucose tolerance test with insulin. Measuring both glucose and insulin at fasting and at intervals after a glucose load reveals the dynamic relationship between glucose challenge and insulin response — providing the most clinically practical assessment of insulin sensitivity without research-grade techniques.
Triglyceride/HDL ratio. A ratio above 3.0 (in mg/dL units) is a validated surrogate marker for insulin resistance, useful when insulin measurements are unavailable.
Reversing insulin resistance
The encouraging news about insulin resistance is that it is substantially reversible through lifestyle intervention — particularly through weight loss, physical activity, and dietary modification.
Weight loss. A reduction of 5-10% of body weight significantly improves insulin sensitivity, with the greatest improvement occurring in the early phases of weight loss. The Diabetes Prevention Program demonstrated that intensive lifestyle intervention producing 7% weight loss reduced progression from prediabetes to diabetes by 58% — more effective than metformin (Knowler et al., 2002).
Exercise. Both aerobic exercise and resistance training improve insulin sensitivity through independent mechanisms. Aerobic exercise increases mitochondrial biogenesis and oxidative capacity in skeletal muscle. Resistance training increases muscle mass (the primary site of insulin-stimulated glucose disposal). The combination of aerobic and resistance training produces the greatest improvement in insulin sensitivity.
Dietary modification. Dietary patterns emphasizing whole foods, fiber, omega-3 fatty acids, and low glycemic index carbohydrates improve insulin sensitivity. Time-restricted eating and intermittent fasting have shown promising effects on insulin sensitivity in some studies, likely mediated through caloric restriction and circadian rhythm optimization.
Sleep. Even modest sleep restriction (5 hours per night for 1 week) produces measurable insulin resistance in healthy young adults. Optimizing sleep duration and quality is an underappreciated and evidence-based strategy for improving insulin sensitivity.
Insulin resistance is not inevitable. It is a metabolic adaptation to environmental conditions — excess caloric intake, physical inactivity, disrupted sleep, chronic stress — that are modifiable. The challenge is not pharmacological but systemic: building health systems, food environments, and social structures that support the metabolic conditions under which human physiology functions as designed.
References
- DeFronzo, R. A. (2004). Pathogenesis of Type 2 diabetes mellitus. Medical Clinics of North America, 88(4), 787–835.
- Knowler, W. C., et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM, 346(6), 393–403.
- Ozcan, U., et al. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 306(5695), 457–461.
- Petersen, K. F., et al. (2004). Mitochondrial dysfunction in the elderly. PNAS, 100(14), 8466–8468.
- Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799–806.
- Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance. Cell, 148(5), 852–871.
- Younossi, Z. M., et al. (2016). Global epidemiology of NAFLD. Hepatology, 64(1), 73–84.
The personal fat threshold hypothesis
One of the most clinically relevant concepts in insulin resistance research is Roy Taylor's "personal fat threshold" hypothesis. Taylor, a diabetes researcher at Newcastle University, proposes that each individual has a genetically determined threshold of adipose tissue capacity — and that insulin resistance and Type 2 diabetes develop when an individual exceeds their personal threshold, regardless of absolute body weight.
This hypothesis explains a clinical observation that has long puzzled researchers: some individuals develop severe insulin resistance and Type 2 diabetes at relatively modest body weights (BMI 25-30), while others remain insulin-sensitive at substantially higher weights (BMI 35-40+). The personal fat threshold varies between individuals and between ethnic groups — South Asian populations, for example, have lower average fat thresholds than European populations, which is why they develop Type 2 diabetes at lower BMI thresholds (Taylor & Holman, 2015).
The clinical implication is that "normal weight" individuals who exceed their personal fat threshold may be insulin-resistant and metabolically unhealthy — the phenomenon of "metabolically obese normal weight" (MONW) or "thin outside, fat inside" (TOFI). Conversely, individuals with high personal fat thresholds may be metabolically healthy despite carrying substantial adipose tissue — "metabolically healthy obesity" (MHO), though the long-term stability of MHO status is debated.
Insulin resistance and the brain
The relationship between insulin resistance and brain function has emerged as a major research frontier. The brain was long considered "insulin-independent" — not requiring insulin for glucose uptake — but this view has been revised. Insulin receptors are abundantly expressed in the hippocampus (critical for memory), prefrontal cortex (executive function), and hypothalamus (appetite and energy regulation), and central insulin signaling plays important roles in synaptic plasticity, neuronal survival, and tau protein phosphorylation (the latter being directly relevant to Alzheimer's disease pathology).
Central insulin resistance — impaired insulin signaling in the brain — has been identified in Alzheimer's disease patients, leading Suzanne de la Monte to propose the provocative hypothesis that Alzheimer's disease is a form of "type 3 diabetes" — a brain-specific insulin resistance syndrome that drives amyloid and tau pathology through impaired insulin-dependent neuroprotective mechanisms (de la Monte & Wands, 2008). While the "type 3 diabetes" label remains controversial, the epidemiological association between Type 2 diabetes and Alzheimer's risk (approximately doubled risk) and the mechanistic connections between insulin signaling and amyloid processing are well-established.
Intranasal insulin — delivered directly to the brain via the olfactory pathway — has shown promise in improving memory and cognitive function in Alzheimer's disease patients in early-phase clinical trials, supporting the hypothesis that central insulin signaling plays a causal role in neurodegeneration (Craft et al., 2012).
The future of insulin resistance management
The management of insulin resistance is evolving beyond traditional lifestyle counseling and metformin:
GLP-1 receptor agonists. Semaglutide and tirzepatide — discussed extensively elsewhere — produce dramatic weight loss and significant improvements in insulin sensitivity, fundamentally altering the treatment landscape for insulin resistance and its downstream metabolic consequences.
Continuous glucose monitoring (CGM). The availability of consumer CGM devices (Dexcom, Libre, Levels) is enabling individuals to visualize their glucose responses to specific foods and activities in real time, providing biofeedback that can guide personalized dietary and lifestyle modifications. The psychological impact of seeing a glucose spike after a meal of refined carbohydrates — when an identical caloric load of protein and fiber produced no spike — is often more motivating than abstract dietary counseling.
Microbiome-targeted interventions. Emerging evidence links specific gut microbiome compositions to insulin sensitivity, and microbiome-targeted interventions (probiotics, prebiotics, fecal microbiota transplantation) are being investigated for metabolic benefit. A landmark study by Kootte et al. demonstrated that fecal transplantation from lean insulin-sensitive donors to obese insulin-resistant recipients produced transient improvements in insulin sensitivity — providing proof-of-concept for microbiome-based metabolic therapies (Kootte et al., 2017).
Insulin resistance is the metabolic undercurrent of the modern world — a condition born of the collision between a genome adapted to scarcity and an environment of unprecedented abundance. Understanding it is the first step toward managing it. The second step — building environments, food systems, and healthcare structures that support metabolic health rather than undermining it — requires a transformation that extends far beyond pharmacology.